Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

7.680 +0.220 (+2.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Altimmune: Q1 Earnings Insights
Via Benzinga
Earnings Preview: Altimmune
Via Benzinga
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023 
Via InvestorPlace
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers. 
Via InvestorPlace
Short Volatility Alert: Altimmune Inc
On Thursday, shares of Altimmune Inc (NASDAQ: ALT) experienced volatile short activity. After the activity, the stock price went down -4.02% to $5.73. The overall sentiment for ALT has been Bearish. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Analysts Have This to Say About Altimmune
Via Benzinga
Analyst Ratings for Altimmune
Via Benzinga
Looking Into Altimmune's Return On Capital Employed
Via Benzinga
Earnings Outlook For Altimmune
Via Benzinga
4 Analysts Have This to Say About Altimmune
Via Benzinga
7 Cheap Stocks That Are Worth Your Attention
Finding cheap stocks that are worth an investment can be tricky, but the Portfolio Grader is a tool you can use to narrow the field. 
Via InvestorPlace
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome... 
Via Benzinga
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making. 
Via The Motley Fool
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP 
Via MarketBeat
Is Viking Therapeutics a Smart Buy on the Dip?
The stock recently fell around 25% for reasons that had nothing to do with its lead program. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2023
Via Benzinga
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
It's not the end of the story for this once high-flying biotech stock. 
Via The Motley Fool
Nasdaq Up Over 100 Points; Crude Oil Rises 2%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.41% to 32,376.61 while the NASDAQ rose 1.05% to 11,798.39.... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. 
Via Benzinga
Gold Drops Over 1%; Existing Home Sales Surge In February
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.65% to 32,455.57 while the NASDAQ rose 0.57% to 11,741.91. The S&P 500,... 
Via Benzinga
META Stock Price Prediction: Can Meta Platforms Really Hit $250?
Meta Platforms (META) stock is worth checking on Tuesday as investors react to a new rating and price target for the shares. 
Via InvestorPlace
Why Is Altimmune (ALT) Stock Down 67% Today?
Altimmune (ALT) stock is losing value on Tuesday after the company released results from a Phase 2 clinical trial for obesity. 
Via InvestorPlace
US Stocks Open Higher; Nasdaq Jumps Over 100 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.90% to 32,535.25 while the NASDAQ rose... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Altimmune Stock Is Diving: What's Going On?
Shares of clinical-stage biopharmaceutical company Altimmune Inc (NASDAQ: ALT) are trading lower Tuesday after the company announced results from an interim analysis of 
Via Benzinga
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.